Entries by admin

Barcelona Liver Bioservices presents novel microfluidic human liver slice model for antifibrotic drug screening at AASLD Meeting: GLP1-R agonist Liraglutide demonstrates antifibrotic activity

Washington DC, November 7th 2025 Barcelona Liver Bioservices (BLB), a leading preclinical research organization specialized in liver disease modeling and drug discovery, is proud to announce the presentation of its latest study entitled “A microfluidic human liver slice model for antifibrotic drug screening: GLP1-R agonist Liraglutide demonstrates antifibrotic activity” at the Annual Meeting of the […]

07/11/2025 /0 Comments/by

Barcelona Liver Bioservices and GAT Therapeutics unveil promising preclinical results of GTX-11 for MASH treatment

July 14, 2025 – Barcelona, Spain  Barcelona Liver Bioservices (BLB) is proud to announce the publication of a groundbreaking study in collaboration withGAT Therapeutics, presenting compelling preclinical evidence for the efficacy of GTX-11 in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)—a rapidly growing global health challenge with no currently approved therapies. The study evaluated GTX-11, a first-in-class compound with anti-inflammatory […]

14/07/2025 /0 Comments/by

Latest BLB research published in the Journal of Hepatology

Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” in the peer-reviewed scientific journal Journal of Hepatology.

02/12/2020 by

Barcelona Liver Bioservices announces collaboration with Surrozen

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with Surrozen, a biotech company developing tissue-specific antibodies that have the potential to regenerate tissue in situations of serious diseases.

01/07/2020 by